Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Antiretrovirals in HIV-1
NCT05585307Phase 1Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of bavtavirine, lepetegravir and GS-6212 in human immunodeficiency virus type 1 infection (HIV-1) (8 cohorts), sponsored by Gilead Sciences. Primary endpoint: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (log10 Copies/mL) at Day 11 Relative to Historical Placebo Data. Started Oct 2022; status: completed.
02
Drugs
bavtavirinelepetegravirGS-6212
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05585307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585307.